Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831219 | 0.73 | CES2 (0.46) | ALDH1A1HPGDRAB9AMAPTMYC | |
| SCHEMBL3626943 | 0.72 | MEN1 (0.44) | ALDH1A1HPGDRAB9ASMN1; SMN2LMNA | |
| SCHEMBL6092124 | 0.72 | RAB9A (0.42) | ALDH1A1HPGDHSD17B10RAB9AMAPT | |
| SCHEMBL31162480 | 0.71 | NPC1 (0.42) | ALDH1A1HPGDHSD17B10RAB9AMAPT | |
| SCHEMBL3304359 | 0.70 | RAB9A (0.44) | ALDH1A1HPGDRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL19545436 | 0.70 | TSHR (0.50) | ALDH1A1HPGDHSD17B10RAB9AMAPT | |
| SCHEMBL1802165 | 0.69 | CES2 (0.50) | ALDH1A1HPGDHSD17B10RAB9ASMN1; SMN2 | |
| SCHEMBL5724714 | 0.69 | THRB (0.46) | ALDH1A1HPGDHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL21376615 | 0.69 | ALDH1A1 (0.46) | ALDH1A1LMNA | |
| SCHEMBL697453 | 0.69 | TDP1 (0.52) | ALDH1A1HPGDHSD17B10MYCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | ALDH1A1 159/4885HPGD 527/4885HSD17B10 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.